Don't Be Too Quick to Jump on the Vascepa (Icosapent Ethyl) Bandwagon
January 2019
You'll hear cautious optimism about cardiovascular benefits with the Rx omega-3 fatty acid, Vascepa (icosapent ethyl)...and see a flood of ads.
Vascepa is a form of EPA (eicosapentaenoic acid). Other Rx omega-3s (Lovaza) or fish oil supplements have EPA and DHA (docosahexaenoic acid).
New evidence suggests Vascepa 2 g BID may prevent a CV event in about one in 21 high-CV-risk patients over 5 years compared to placebo. This is in patients with elevated triglycerides of about 215 mg/dL despite statins...and CV disease OR diabetes plus other CV risks (high BP, etc).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote